Madrigal Pharmaceuticals
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $364,252 | $311,337 | $321,083 | $287,268 |
Gross Profit | 324,245 | 284,490 | 296,635 | 269,146 |
EBITDA | -56,308 | -86,186 | -49,886 | -106,381 |
EBIT | -86,572 | -50,278 | -106,739 | |
Net Income | -57,939 | -94,391 | -58,575 | -114,190 |
Net Change In Cash | 364,252 | 311,337 | 321,083 | 287,268 |
Free Cash Flow | 19,076 | -171,284 | -133,070 | 78,993 |
Cash | 292,726 | 232,188 | 198,693 | 295,694 |
Basic Shares | 29,145 | 29,032 | 22,434 | 22,482 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $958,403 | $180,133 | $0 | $0 |
Gross Profit | 902,255 | 173,900 | 0 | 0 |
EBITDA | -264,469 | -450,125 | -360,391 | -290,919 |
EBIT | -265,975 | -451,221 | -360,918 | -291,386 |
Net Income | -288,284 | -465,892 | -373,630 | -295,350 |
Net Change In Cash | 958,403 | 180,133 | 0 | 0 |
Cost of Revenue | 295,280 | |||
Free Cash Flow | -190,020 | -457,034 | -325,709 | -225,074 |
Cash | 198,693 | 100,019 | 99,915 | 331,549 |
Basic Shares | 22,434 | 21,272 | 18,688 | 17,137 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$1.99 |
2026-03-31 | -$1.38 |
2025-12-31 | -$2.57 |
2025-09-30 | -$4.96 |